233 related articles for article (PubMed ID: 21349995)
1. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Fazli L; Gleave ME; Zoubeidi A
Clin Cancer Res; 2011 Apr; 17(8):2301-13. PubMed ID: 21349995
[TBL] [Abstract][Full Text] [Related]
2. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
3. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
[TBL] [Abstract][Full Text] [Related]
4. SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.
Okawa Y; Hideshima T; Steed P; Vallet S; Hall S; Huang K; Rice J; Barabasz A; Foley B; Ikeda H; Raje N; Kiziltepe T; Yasui H; Enatsu S; Anderson KC
Blood; 2009 Jan; 113(4):846-55. PubMed ID: 18948577
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
6. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
[TBL] [Abstract][Full Text] [Related]
7. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
8. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
9. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
10. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Kuruma H; Beraldi E; Fazli L; Zoubeidi A; Gleave ME
Cancer Res; 2011 Sep; 71(17):5838-49. PubMed ID: 21737488
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
12. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells.
Wang SX; Ju HQ; Liu KS; Zhang JX; Wang X; Xiang YF; Wang R; Liu JY; Liu QY; Xia M; Xing GW; Liu Z; Wang YF
Biosci Biotechnol Biochem; 2011; 75(8):1540-5. PubMed ID: 21821931
[TBL] [Abstract][Full Text] [Related]
13. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
Seaton A; Maxwell PJ; Hill A; Gallagher R; Pettigrew J; Wilson RH; Waugh DJ
Br J Cancer; 2009 Nov; 101(9):1620-9. PubMed ID: 19809428
[TBL] [Abstract][Full Text] [Related]
15. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
17. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
18. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
19. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
20. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]